Expression of cell cycle regulator p27(Kip1) is correlated with survival of patients with astrocytoma

Clinical Cancer Research

Volumn 5, Issue 3, 1999, Pages 551-557

  Mizumatsu, Shinichiro ^a   Tamiya, Takashi ^a   Ono, Yasuhiro ^a   Abe, Tomoyasu ^a   Matsumoto, Kengo ^a   Furuta, Tomohisa ^a   Ohmoto, Takashi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; KI 67 ANTIGEN; PROTEIN P27;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KI-67 ANTIGEN; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0033066580     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hunter, T., and Pines, J. Cyclins and cancer. II. Cyclin D and cdk inhibitors come of age. Cell, 79: 573-582, 1994.
2. 1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
3. 1 control in mammalian cells. J. Cell Sci. Suppl., 18: 69-73, 1994.
4. Nouese, J., Firpo, E., Flanagan, M., Caots, S., Polyak, C., Lee, M., Massague, J., Crabtree, G., and Roberts, J. Interleukin-2-mediated elimination of p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (Lond.), 372: 570-573, 1994.
5. Coats, S., Flannagan, W., Nourse, J., and Roberts, J. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science (Washington DC), 272: 877-880, 1996.
6. Ono, Y., Tamiya, T., Ichikawa, T., Kunishio, K., Matsumoto, K., Furuta, T., Ohmoto, T., Ueki, K., and Louis, D. N. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J. Neuropathol. Exp. Neurol., 55: 1026-1031, 1996.
7. Ono, Y., Tamiya, T., Ichikawa, T., Matsumoto, K., Furuta, T., Ohmoto, T., Akiyama, K., Seki, S., Ueki, K., and Louis, D. N. Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression. Acta Neuropathol., 94: 21-27, 1997.
8. Ferrando, A. A., Balbin, M., Pendas, A. M., Vizoso, F., Velasco, G., and Lopes-Otin, C. Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas. Hum. Genet., 97: 91-94, 1996.
9. Kawamata, N., Morosetti, R., Miller, C. W., Park, D., Spirin, K. S., Nakamaki, T., Takeuchi, S., Hatta, Y., Simpson, J., Wilczynski, S., Young, Y. L., Bartram, C. R., and Koeffler, H. P. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res., 55: 2266-2269, 1995.
10. kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55: 1206-1210, 1995.
11. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res., 55: 1211-1214, 1995.
12. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of ubiquitin-protease pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Washington DC), 269: 682-685, 1995.
13. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med, 3: 222-225, 1997.
14. Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
15. Tan, P., Cady, B., Wanner, M., Worland, P., Cukor, B., Magi-Galluzzi, C., Lavin, P., Draetta, G., Panago, M., and Loda, M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res., 57: 1259-1263, 1997.
16. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
17. Mori, M., Mimori, K., Shiraishi, T., Tanaka, S., Uco, H., Sugimachi, K., and Akiyoshi, T. p27 expression and gastric carcinoma. Nat. Med., 3: 593, 1997.
18. kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58: 542-548, 1998.
19. Shapiro, W. R. Treatment of neuroectodermal brain tumors. Ann. Neurol., 12: 231-237, 1983.
20. Burger, P. C. Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment. Semin. Oncol., 13: 16-26, 1986.
21. Burger, P. C., and Green, S. B. Patient age, histological features, and length of survival in patients with glioblastoma multiforme. Cancer (Phila.), 59: 1617-1625, 1987.
22. Burger, P. C., Vogel, F. S., Green, S. B., and Strike, T. A. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer (Phila.), 56: 1106-1112, 1985.
23. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., Giordano, G. G., Caputi, M., Baldi, F., Pagano, M., and Giordano, A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res, 57: 3381-3385, 1997.
24. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
25. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep, 50: 163-170, 1966.
26. Cox, D. R. Regression models and life tables. J. R. Stat. Soc. B, 34: 187-220, 1972.
27. Gratzner, H. G. Monoclonal antibody of 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science (Washington DC), 218: 474-476, 1982.
28. Gerdes, J., Schwab, V., Lemke, H., and Stein, H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer, 31: 13-20, 1983.
29. Hoshino, T., Prados, M., Wilson, C. B., Gho, K. G., Lee, K-S., and Davis, R. L. Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. J. Neurosurg., 71: 335-341, 1989.
30. Zuber, P., Hamou, M. F., and de Tribolet, N. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery, 22: 364-368, 1988.
31. Sallinen, P. K., Haapasalo, H. K., Visakorpi, T., Helen, P. T., Rantala, I. S., Isola, J. J., and Helin, H. J. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J. Pathol., 174: 275-282, 1994.
32. Onda, K., Davis, R. L., Shibuya, M., Wilson, C. B., and Hoshino, T. Correlation between the bromodeoxyuridine labeling index and the MIB-I and Ki-67 proliferating cell indices in cerebral gliomas. Cancer (Phila.), 74: 1921-1926, 1994.
33. Cunningham, J. M., Kimmel, D. W., Scheithauer, B. W., O'Fallon, J. R., Novotny, P. J., and Jenkins, R. B. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J. Neurosurg., 86: 121-130, 1997.
34. Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., and Louis, D. N. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res., 56: 150-153, 1996.
35. Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Polyak, K., Firpo, E., Tsai, L., Broudy, V., Perlmutter, R. M., Kaushansky, K., and Roberts, J. M. A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27Kip1-deficient mice. Cell, 85: 733-744, 1996.
36. Kiyokawa, H., Kineman, R. D., Manova-Todorova, K. O., Soares, V. C., Hoffman, E. S., Ono, M., Khanam, D., Hayday, A. C., Frohman, L. A., and Koff, A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell, 85: 721-732, 1996.
37. Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., and Nakayama, K. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707-720, 1996.
38. Hengst, L., and Reed, S. I. Translational control of p27Kip1 accumulation during the cell cycle. Science (Phila.), 271: 1861-1864, 1996.
39. Piva, R., Cavalla, P., Bortolotto, S., Cordera, S., Richiardi, P., and Schiffer, D. p27/kip1 expression in human astrocytic gliomas. Neurosci Lett, 234: 127-130, 1997.
40. Jaros, E., Perry, R. H., Adam, L., Kelly, P. J., Crawford, P. J., Kalbag, R. M., Mendelow, A. D., Sengupta, R. P., and Pearson, A. D. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumors. Br. J. Cancer. 66: 373-385, 1992.
41. Louis, D. N., Edgerton, S., Thor, A. D., and Hedley-Whyte, E. T. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol., 81: 675-679, 1991.
42. Daumas-Duport, C., Scheithauer, B. W., and Kelly, P. J. A histologic and cytologic method for the spatial definition of gliomas. Mayo Clin. Proc., 62: 435-449, 1987.